BIOTRICITY INC.

BIOTRICITY INC. is a medical technology company that provides biometric data monitoring solutions. The company delivers remote monitoring solutions to the medical, healthcare, and consumer markets, concentrating on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. For diagnostic remote patient monitoring, BIOTRICITY INC. applies innovation within existing business models where reimbursement is established. In post-diagnostic markets, the company aims to use medical-grade biometrics to enable consumers to self-manage. BIOTRICITY INC. initially focused on the ambulatory diagnostic cardiac outpatient market, specifically Mobile Cardiac Outpatient Monitoring ("COM"), while also offering capabilities for all types of ambulatory cardiac studies. The company developed its Bioflux® ("Bioflux") COM technology, which includes a monitoring device and software components and has received clearance from the U.S. Food and Drug Administration ("FDA"). Bioflux was released in a limited capacity on April 6, 2018, to assess sales processes and market dynamics, with a full market release for commercialization occurring in April 2019. The fiscal year ended March 31, 2021, was the first year of expanded commercialization efforts for Bioflux, focusing on sales growth and expansion. In 2021, the company launched Bioheart, a direct-to-consumer heart monitor that utilizes the same continuous heart monitoring technology as Bioflux. In 2022, BIOTRICITY INC. launched its Biocore Cardiac Monitoring Device ("Biocore", previously branded as Biotres), a three-lead device for ECG and arrhythmia monitoring designed for lower-risk patients. Late in 2024, the company launched the cellular version of this device, the Biocore Pro, which is now its flagship technology.